Previous evidence has demonstrated that the relationship between hypoxia and PD-L1, and PD-L1 is a predictive biomarker for the efficacy of immunotherapy and contributes to disease progression with evasion from tumor immunity. The gene discussed is CD274; the disease is neoplasm.